Valuation: Decoy Therapeutics Inc.

Market Cap 2.19M 1.9M 1.77M 1.62M 3.07M 209M 3.11M 20.85M 8.18M 104M 8.21M 8.03M 348M P/E 2024 *
-
P/E 2025 -0.06x
Enterprise Value -8.52M -7.41M -6.9M -6.33M -11.96M -814M -12.14M -81.29M -31.91M -405M -32.01M -31.31M -1.36B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.41%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Decoy Therapeutics Inc.

1 day+4.85%
1 week-18.45%
1 month-46.06%
3 months-30.34%
6 months-55.57%
Current year-47.21%
1 week 3.51
Extreme 3.51
4.45
1 month 3.51
Extreme 3.51
8.12
Current year 3.51
Extreme 3.51
16.92
1 year 3.51
Extreme 3.51
120.6
3 years 3.51
Extreme 3.51
1,425.6
5 years 3.51
Extreme 3.51
43,199.97
10 years 3.51
Extreme 3.51
533,353.97
Date Insider Type Main position Quantity % Market Cap.
12/30/25 Sell

Director

27 0.0005%
11/20/25 Buy

Director

5,000 0.1402%
11/20/25 Buy

Chief Financial Officer

20,000 0.5608%
Change 5-day change 1-year change 3-year change Capi.($)
+4.85%-18.45%-96.38%-99.68% 2.19M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average +0.37%-5.26%+22.64%+129.36% 23.39B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2024 2025
Net sales - -
Net income -5.58M -4.85M -4.51M -4.14M -7.82M -532M -7.94M -53.18M -20.87M -265M -20.94M -20.48M -889M -12.52M -10.88M -10.13M -9.3M -17.56M -1.2B -17.83M -119M -46.86M -595M -47.01M -45.98M -1.99B
Net Debt -2.21M -1.92M -1.79M -1.64M -3.1M -211M -3.15M -21.1M -8.28M -105M -8.31M -8.13M -353M -10.71M -9.31M -8.67M -7.96M -15.02M -1.02B -15.26M -102M -40.09M -509M -40.22M -39.34M -1.71B
Logo Decoy Therapeutics Inc.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
11
Date Price Change Volume
26-07-31 US$4.110 +4.85% 16,247
26-07-30 US$3.920 -2.73% 32,355
26-07-29 US$4.030 -0.25% 49,138
26-07-28 US$4.040 +8.02% 88,237
26-07-27 US$3.740 -25.79% 1,088,494

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCOY Stock